The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: A systematic review and meta-analysis of randomized controlled trials
Background
Patients with non-alcoholic fatty liver disease (NAFLD) benefit from using synbiotics. However, findings from existing trials remain contentious. Therefore, this meta-analysis evaluated the effects of synbiotics on liver enzymes, blood pressure, inflammation, and lipid profiles in patients with NAFLD.
Methods
We searched PubMed, Embase, Cochrane, Scopus, and Web of Science for randomized controlled trials (RCTs) regarding synbiotics supplementation in patients with NAFLD.
Results
The meta-analysis revealed that synbiotics supplementation significantly improved liver enzymes (AST, WMD: −9.12 IU/L; 95 % CI: −13.19 to −5.05; ALT, WMD: −8.53 IU/L; 95 % CI: −15.07 to −1.99; GGT, WMD: −10.42 IU/L; 95 % CI: −15.19 to −5.65), lipid profile (TC, WMD: −7.74 mg/dL; 95 % CI: −12.56 to −2.92), obesity indices (body weight, WMD: −1.95 kg; 95 % CI: −3.69 to −0.22; WC, WMD: −1.40 cm; 95 % CI: −2.71 to −0.10), systolic blood pressure (SBP, WMD: −6.00 mmHg; 95 % CI: −11.52 to −0.49), and inflammatory markers (CRP, WMD: −0.69 mg/L; 95 % CI: −1.17 to −0.21; TNF-α, WMD: −14.01 pg/mL; 95 % CI: −21.81 to −6.20).
Conclusion
Overall, supplementation with synbiotics positively improved liver enzymes, obesity indices, and inflammatory cytokines in patients with NAFLD.
期刊介绍:
Pharmacological Research publishes cutting-edge articles in biomedical sciences to cover a broad range of topics that move the pharmacological field forward. Pharmacological research publishes articles on molecular, biochemical, translational, and clinical research (including clinical trials); it is proud of its rapid publication of accepted papers that comprises a dedicated, fast acceptance and publication track for high profile articles.